Patents by Inventor Ahuva BAR-ILAN

Ahuva BAR-ILAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210008172
    Abstract: Compositions which include polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus or amino terminus of an insulin-like growth factor 1 (IGF-1) or IGF-1 variant. Polynucleotides encoding the same are disclosed. Pharmaceutical compositions and pharmaceutical formulations comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Application
    Filed: July 9, 2020
    Publication date: January 14, 2021
    Applicant: OPKO Biologics Ltd.
    Inventors: OREN HERSHKOVITZ, Lital Israeli-Yagev, Ahuva Bar-Ilan, Laura Moschcovich, Moran Golan
  • Publication number: 20200254065
    Abstract: Compositions which include glucagon-like peptide-2 (GLP-2) analogs, GLP-2 analogs with reversible or non-reversible linkers attached to one or more amino acid positions of the GLP-2 analog, and GLP-2 analogs linked to one or more polyethylene glycol polymers (PEG) via reversible or non-reversible linkers are disclosed. Also disclosed are pharmaceutical compositions comprising: the GLP-2 analogs; GLP-2 analogs linked solely to reversible or non-reversible linkers; the reverse PEGylated GLP-2 analogs; and the non-reversibly PEGylated GLP-2 analogs, as well as methods of using the same.
    Type: Application
    Filed: February 11, 2020
    Publication date: August 13, 2020
    Applicant: OPKO Biologics Ltd.
    Inventors: Oren Hershkovitz, Ahuva Bar-Ilan, Vered Lev
  • Publication number: 20190160152
    Abstract: Pharmaceutical formulations and pharmaceutical compositions comprising reverse PEGylated oxyntomodulin conjugates, and methods of producing, and using the same are described. Conjugates include those attaching a polyethylene glycol polymer (PEG polymer) and 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS) to a oxyntomodulin peptide, wherein the PEG polymer is attached to the amino terminus or to an amino residue within the oxyntomodulin via a flexible linker, wherein the flexible linker comprises a Fmoc or a FMS.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 30, 2019
    Applicant: OPKO BIOLOGICS LTD.
    Inventors: Oren HERSHKOVITZ, Ahuva BAR-ILAN, Vered LEV, Yaron TZUR
  • Patent number: 9808534
    Abstract: This invention is directed to the use of a chorionic gonadotrophin carboxy terminal peptide (CTP) or fragments thereof for modifying a polypeptide or a fragment thereof in order to increase the hydrodynamic volume of the polypeptide or fragment thereof.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: November 7, 2017
    Assignee: OPKO Biologics Ltd.
    Inventors: Oren Hershkovitz, Ahuva Bar-Ilan
  • Publication number: 20140316112
    Abstract: This invention is directed to the use of a chorionic gonadotrophin carboxy terminal peptide (CTP) or fragments thereof for modifying a polypeptide or a fragment thereof in order to increase the hydrodynamic volume of the polypeptide or fragment thereof.
    Type: Application
    Filed: November 20, 2013
    Publication date: October 23, 2014
    Inventors: Oren HERSHKOVITZ, Ahuva BAR-ILAN